The objective of this study was to test the hypothesis that dsRNA promotes lung inflammation and alters airway responsiveness to cholinergic and ␤-adrenergic receptor agonists in human lung slices. Human airway smooth muscle (ASM) was incubated for 24 h in poly(I:C) Ϯ TNF␣ and a TLR3 monoclonal antibody. Precision-cut lung slices (PCLS; 250-m thickness) from healthy human lungs containing a small airway were incubated in 0, 10, or 100 g/ml poly(I:C) for 24 h. Intravital microscopy of lung slices was used to quantify contractile and relaxation responsiveness to carbachol and isoproterenol, respectively. Supernatants of ASM and PCLS were analyzed for cytokine secretion using a 25-multiplex bead assay. In human ASM, poly(I:C) (0.5 g/ml) increased macrophage inflammatory protein-1␣ (MIP-1␣) and RANTES that was prevented by a TLR3 monoclonal receptor antibody. Incubation of human PCLS with poly(I:C) (10 and 100 g/ml) had little effect on the log EC50 or maximum drug effect (Emax) for contraction and relaxation in response to carbachol and isoproterenol, respectively.
airway smooth muscle; precision-cut lung slices; Toll-like receptor 3 ASTHMA and chronic obstructive pulmonary disease (COPD) are characterized by airway obstruction and inflammation. Viral or bacterial infections induce exacerbations and increase the morbidity of patients with chronic airways diseases. A viral infection triggers an innate immune response through host detection of viral double-stranded (ds) RNA via several different mechanisms, including activation of a member of the class of pattern recognition receptors, Toll-like receptor 3 (TLR3). A synthetic dsRNA TLR3 agonist, polyinosinic-polycytidylic acid [poly(I: C)], activates these receptors, which are located on the cellular plasma membrane and intracellular endosomal compartments in a multitude of cell types, including immune, epithelial, and airway smooth muscle (ASM) cells in the lung.
Evidence suggests in cultured human airway epithelial and smooth muscle cells that poly(I:C) stimulation in a TLR3-dependent manner increases cytokine or chemokine secretion. For example, in airway epithelial cells, Haemophilus influenzae increases expression of TLR3 (23) , and poly(I:C) increases the mRNA expression of TLR3 and the secretion of cytokines [e.g., IL-1␤, granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-6, and TNF␣] and chemokines [e.g., CXCL10/IFN-␥-inducible protein 10 (IP-10), CCL5/RANTES, CCL3/macrophage inflammatory protein-1␣ (MIP-1␣), and CXCL8/IL-8] (14, 20, 29) . In normal human bronchi, TLR3 agonists stimulate epithelial cells to express thymic stromal lymphopoietin (TSLP), a molecule associated with T cell (Th2) responses that is increased in asthma patients (13) . In addition, human rhinovirus or dsRNA increases T cell-interacting ligands in human airway epithelial cells (8) . ASM cells preferentially express TLR3 (16 -18, 26) over other TLRs (26) , and dsRNA induces cytokine and eosinophilic chemokine release (18, 26) . Therefore, since viruses are associated with exacerbations of airway inflammatory responses, TLR3 activation may play a key role in promoting exacerbations in COPD and asthma. Similar to these in vitro findings, in vivo rodent data demonstrate that TLR3 activation modulates to lung inflammation (12, 22) .
Few studies address whether TLR3 activation affects agonist-induced airway responsiveness in addition to lung inflammation, but in ovalbumin (OVA)-sensitized rats, poly(I:C) enhanced airway hyperresponsiveness (AHR) to carbachol (25) and, in isolated mouse tracheal rings, incubation in poly(I:C) or lipopolysaccharide enhanced contraction in response to bradykinin (2) .
Recent evidence suggests that poly(I:C) increased muscarinic M 3 receptor expression in human ASM and enhanced the acetylcholine-induced calcium flux response (16) . That study suggests that poly(I:C) may contribute, at least in part, to AHR via a direct local effect on ASM in the human lung. To test whether poly(I:C) incubation could have a local direct effect on enhance human lung tissue contractile/relaxing or synthetic responsiveness, we used organotypic culture of precision-cut lung slices (PCLS) that were obtained from donor lungs as we (6) reported previously. This method allows visualization of tissue responses to carbachol and isoproterenol in small airways that are kept patent by their intact matrix environment. Cytokine secretion was also measured in a manner similar to that reported in lung slices previously (3, 4). Our approach enables direct comparison of poly(I:C) responsiveness of both the multiple cell types in situ that contribute to the inflammatory response and the ASM receptors that mediate tone in the same tissue. Our data suggest that TLR3 activation promotes cytokine and chemokine secretion without modulation bronchoconstriction or bronchodilatation.
METHODS
Reagents. All reagents [carbachol, isoproterenol, low melting point agarose (IX-A), Ham's F-12 medium (supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 2.5 g/ml Fungizone, 50 g/ml gentamicin, 1 M HEPES; pH 7.6)] were obtained from Sigma (St. Louis, MO) unless otherwise stated. Poly(I:C) was obtained from GE Amersham as a lyophile and reconstituted to 2 mg/ml in PBS while heating at 50°C for Ͼ6 h. Aliquots were stored at Ϫ20°C, thawed at 37°C before use, and maintained at 4°C.
Human ASM cell cultures. Human ASM cells, plated on plastic without substrate, were derived from trachea, which was obtained from the National Disease Research Interchange (NDRI; Philadelphia, PA). Human ASM cell culture was performed as described previously (19) . Briefly, a segment of trachea just proximal to the carina was removed under sterile conditions, and the tracheal muscle was isolated. The muscle was then centrifuged and resuspended in 10 ml of buffer containing 0.2 mM CaCl 2, 640 U/ml collagenase, 1.0 mg/ml soybean trypsin inhibitor, and 10 U/ml elastase. Enzymatic dissociation of the tissue was performed for 90 min in a shaking water bath at 37°C. The cell suspension was filtered through 105-mm Nitex mesh, and the filtrate was washed with equal volumes of cold Ham's F-12 medium supplemented with 10% FBS (HyClone, Logan, UT). Aliquots of the cell suspension were plated at a density of 1.0 ϫ 10 4 cells/cm 2 . The cells were cultured in Ham's F-12 medium supplemented with 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2.5 mg/ml amphotericin B, and this was replaced every 72 h. Human ASM cells in subculture during passages 1-5 were used, as these cells retain native contractile protein expression as demonstrated by immunocytochemical staining for smooth muscle actin and myosin (19) . Confluent ASM cells were grown to ϳ75% confluence in SMGM medium (Lonza) with 5% bovine serum albumin and incubated in a range of concentrations of poly(I:C) (0.001-10 g/ml) in the presence or absence of TNF␣ (10 ng/ml) for 24 h. In separate experiments, cells were incubated in 0.5 g/ml poly(I:C) and 10 ng/ml TNF␣ in the presence of a range of concentrations of a TLR3-specific MAb or isotype control generated in house. The conditions were performed in duplicate wells in a total of four different experiments. The same TLR3 MAb inhibited the cytokine/ chemokine response induced by nontypeable H. influenzae in primary normal human bronchial epithelial cells. Briefly, this MAb inhibits poly(I:C)-induced NF-B and IFN-stimulated response element (ISRE) activation in reporter gene assays in a TLR3-selective manner. In human embryonic kidney (HEK)-293 cells transfected with human TLR3, but not empty vector control cells, the luciferase ratio of NF-B or ISRE relative light units (RLU) to control RLU was increased by 0.1 g/ml poly(I:C); however, in the presence of MAb (0.0032-50 g/ml), ISRE and NF-B activation were inhibited by the MAb, with IC 50s of 0.2 and 0.48 g/ml, respectively (F. Teng, V. Slavik, K. Duffy, L. San Mateo, and R. Goldschmidt, unpublished observations).
Human lung slice preparation. Human PCLS were prepared as previously described (6) . Briefly, healthy whole human lungs were received from the NDRI, and the smallest lobe was dissected out and its main bronchus identified. The lobe was inflated using a 2% (wt/vol) low melting point agarose solution. Once the agarose had set, the lobe was sectioned, and cores of 8-mm diameter were made. The cores that contained a small airway by visual inspection were sliced at a thickness of 250 m (Krumdieck Tissue Slicer; model no. MD4000; Alabama Research and Development) and collected in wells containing supplemented Ham's F-12 medium. Suitable airways (Յ1-mm diameter) on slices were selected on the basis of the following criteria: presence of a full smooth muscle wall (i.e., cut perpendicular to direction of airway); presence of beating cilia to eliminate blood vessels; and unshared muscle walls at airway branch points to eliminate possible counteracting contractile forces. Each slice was approximated to contain ϳ98% parenchyma tissue; hence, all airways situated on a slice had sufficient parenchymal tissue to satisfy its own baseline tone. Adjacent slices containing contiguous segments of the same airway were paired to act as control to the variable tested and incubated at 37°C on a rotating platform in a humidified air-CO 2 (95-5%) incubator. Sections were placed in fresh media every 2-3 h during the remainder of day 1 and all of day 2 to rid the slice and media of agarose and endogenous substances released that could variably confound the production of inflammatory mediators and/or alter airway tone. Poly(I:C) (10 or 100 g/ml) was then added to one of the paired slices. In parallel studies, to serve as positive controls, IL-13 (100 ng/ml) or TNF␣ (100 ng/ml) were incubated with slices for 18 h, and their effects on airway smooth muscle contractility were assessed. Also, slices were preincubated with either IgE or IgG (4 g/ml) antibodies for 18 h. A time course was carried out measuring airway lumen area every 30 s for 10 min or until no further contraction was observed following the administration of anti-IgE (20 g/ml). To confirm maximum contraction, a high concentration of carbachol (100 M) was added at the end.
After 24 h, lung slices were placed in a 12-well plate in 1.0-ml buffer and held in place using a platinum weight with nylon attachments. The airway was located using a microscope (Nikon Eclipse; model no. TE2000-U; magnification, ϫ40) connected to a live video feed (Evolution QEi; model no. 32-0074A-130 video recorder). A baseline image was taken followed by the addition of the lowest concentration of carbachol to begin the concentration response (10 Ϫ8 to 10 Ϫ4 M). Images were collected 10 min after each dose. Once the airway had reached ϳ90% full contraction or would not contract further, the ␤-adrenoceptor activity was examined by carrying out a full concentration response to isoproterenol (10 Ϫ9 to 10 Ϫ5 M) in the presence of the final concentration of carbachol. Images were taken 5 min after each dose until no further relaxation occurred. Times between doses were determined by previous studies (data not shown).
Airway lumen area was measured using a macro written within Image-Pro Plus software (version 6.0; Media Cybernetics) and given in units of square micrometers. After functional studies, the area of each airway at baseline and at the end of each dose of agonist was calculated using the same macro written within Image-Pro Plus software. A log EC50 value and maximum drug effect (Emax) value for each airway was derived from a concentration-response curve.
Supernatants were collected after 24-h incubation, frozen, and stored at Ϫ80°C. Aliquots were assayed for cytokine secretion using a multiplex bead assay for detection of IL-1␤, IL-1RA, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-13, IL-15, IL-17, TNF␣, IFN-␣, IFN-␥, GM-CSF, MIP-1␣, MIP-1␤, IP-10, monokine induced by IFN-␥ (MIG), eotaxin, RANTES, and monocyte chemoattractant protein-1 (MCP-1) (Invitrogen-BioSource). Samples were diluted 1:2 and 1:10 in assay buffer following the manufacturer's protocol. Sample acquisition and analysis were performed using the Luminex 100 IS (Luminex, Austin, TX) with STarStation software (Applied Cytometry Systems, Sacramento, CA). Where the level was below level of detection according to the standard curves, a zero reading was assigned for that sample.
For all studies, in donor 1, four lung slices were incubated in 0 (n ϭ 4) and 100 g/ml poly(I:C) (n ϭ 4), whereas for donors 2-4, the distribution of treatment groups for the slices was 0 (n ϭ 2), 10 (n ϭ 4), and 100 g/ml (n ϭ 2). Data are expressed as means Ϯ SE. Statistical difference was shown by using a nonpaired t-test or ANOVA. For the data of secreted protein concentrations, logarithmic transformations were performed before analyses to better satisfy the underlying statistical modeling assumptions of equal variability. A one-way ANOVA with Bonferroni multiple comparison test was performed on logarithmic transformed data.
RESULTS

Poly(I:C)-induced mediated cytokine release requires TLR3 activation in human ASM cells.
Incubation of human ASM in concentrations of poly(I:C) (0.01-10 g/ml) for 24 h increased the level of chemokines and cytokines in the supernatants. A representative example was the MIP-1␣/CCL3 response to poly(I:C), which resulted in similar maximal levels obtained at 0.1-10 g/ml (Fig. 1A) . The chemokine responsiveness was increased by the addition of 10 ng/ml TNF␣ (Fig. 1A) , and, based on this, a concentration of 0.5 g/ml poly(I:C) with 10 ng/ml TNF␣ was used to test the TLR3 selectivity of the poly(I:C)-mediated response in these cells in four different experiments using a TLR3 MAb. A representative experiment demonstrates that the increase in MIP-1␣ in the presence of poly(I:C) and TNF␣ was reduced to that of levels induced by TNF␣ (10 ng/ml) alone by the TLR3 MAb (Fig. 1B) . The inhibition by the TLR3 MAb was concentration-dependent with an IC 50 of 0.0016 g/ml. Similarly, increasing concentrations of poly(I:C) in the presence of TNF␣ (10 ng/ml) increased the level of RANTES/CCL5 (Fig. 1C) . The increase in RANTES/CCL5 in the presence of poly(I:C) (50 g/ml) and TNF␣ (10 ng/ml) was reduced to that of levels induced by TNF␣ (10 ng/ml) alone by the TLR3 MAb with an IC 50 of 0.0066 g/ml (Fig. 1D) . In contrast, an isotype control had no effect on ASM cell chemokine responses to the same concentration of poly(I:C) (Fig. 1, B and D) .
Poly(I:C) induces a robust cytokine and chemokine response in an integrated human cell system. Concentrations of poly(I:C) (10 or 100 g/ml; 24 h) based on the reported concentration used in a mouse organ culture experiment (2) were used to determine cytokine responses in the PCLS. Incubation of human lung slices for 24 h in both concentrations of poly(I:C) stimulated the release of detectable levels of most inflammatory cytokines tested vs. PCLS incubated in media alone. When compared for individual donors (Fig. 2) , the levels of cytokines detected in response to control and poly(I:C) incubation were very consistent (Fig. 2) . In one case (donor 2), control levels were lower, although the increase was similar in response to poly(I:C) compared with the other donors. These examples demonstrate that incubation with poly(I:C) markedly increased the concentration of cytokines (e.g., TNF␣, IL-6) and chemokines (e.g., CCL5/RANTES, CCL3/MIP-1␣).
On the basis of the cytokine responses to poly(I:C) observed between donors, we pooled the data from individual lung slices arising from 3-4 donors for each condition. The compiled data for 16 other proteins (Fig. 3) as well as for the functional responses (Fig. 4) are pooled from samples as follows: medium only and 100 g/ml poly(I:C), n ϭ 6 from 3 donor lungs or n ϭ 10 from 4 donor lungs; 100 g/ml, n ϭ 12 in 3 donor lungs. The compiled data illustrate that incubation of 10 or 100 g/ml poly(I:C) for 24 h significantly increased the level of a number of cytokines/chemokines including TNF␣, CCL5/RANTES, CCL3/MIP-1␣, IL-4, IL-6, CXCL8/IL-8, and CXCL10/IP-10. There were no differences in response to 10 and 100 g/ml poly(I:C), with 10 g/ml being sufficient for maximal protein release (Fig. 3) . Values for 4 proteins Fig. 2 . Representative examples of cytokine levels induced after 24-h incubations with 3 different concentrations (0, 10, and 100 g/ml) of poly(I:C) in lung slices from 4 different donor lungs illustrated as means Ϯ SE of replicates within a donor. X indicates that no sample was available for this condition. (IL-5, CCL11/eotaxin, IL-2, and IFN-␣) are not shown due to undetectable levels. Furthermore, IL-1␤, IL-7, IL-15, IL-13, and GM-CSF were proteins that did not change markedly in response to poly(I:C).
Poly(I:C) has little effect on human small airway contraction or relaxation, respectively.
Having demonstrated a robust cytokine and chemokine response following the incubation of poly(I:C) at concentrations of 10 and 100 g/ml, the effect of the TLR3 agonist on small airway contraction and relaxation was investigated. The highest concentration of poly(I:C) had no effect on human small airway sensitivity to carbachol (10 Ϫ4 to 10 Ϫ8 M; Fig. 4A ). Similarly, in submaximally contracted lung slices, addition of isoproterenol (10 Ϫ4 to 10 Ϫ9 M) induces synonymous relaxations in each of the three groups (Fig. 4B) . The calculated log EC 50 and E max values for the responses to carbachol and isoproterenol are not significantly different after 24-h incubation in 0, 10, and 100 g/ml poly(I:C) (Fig. 4, C and D). There were no differences in the basal (24-h incubation) or maximally contracted luminal areas at the start of the cumulative concentration curves for carbachol or isoproterenol, respectively (data not shown).
IL-13 and TNF␣, known to increase airway responsiveness in human ASM and rodents (1, 28) , was assessed in PCLS as a model to detect increased airway sensitivity to carbachol. Pretreatment of PCLS with IL-13 (100 ng/ml) for 18 h decreased in the log EC 50 values (Ϫ0.63 Ϯ 0.06 vs. Ϫ1.06 Ϯ 0.13 M; P ϭ 0.009) and increased the maximum contraction (72.7 Ϯ 8.7 vs. 93.0 Ϯ 2.58%; P ϭ 0.04) for carbacholinduced luminal diameter narrowing. A decrease in log EC 50 values was also observed following incubation of slices with TNF␣ (100 ng/ml) for 18 h (Ϫ0.95 Ϯ 0.08 M; P ϭ 0.01) as shown in Fig. 5A .
Human small airways contracted 60% following the addition of anti-IgG to slices preincubated with the antibody IgE, which was 75% of total contraction following a maximal concentration of carbachol. In comparison, airways preincubated with IgG contracted to 20%, possibly due to nonspecific binding found in the airway slice.
DISCUSSION
In the present study, we showed that poly(I:C) increased chemokine release from human ASM cells via TLR3; however, in human lung explant tissue, poly(I:C), even at high concentrations, had no discernable effect on agonist-induced luminal narrowing or relaxation despite the induction of cytokine and chemokine secretion from the same tissue. The absence of a local direct effect of poly(I:C) on AHR in this study is discussed in light of the methodology used. The evidence for poly(I:C)-induced hyperactivity in other studies in vivo may reflect species differences or depend on intact neuroimmune pathways outside of the lung.
Several studies have investigated cytokine secretion from sliced human lung tissue in response to various stimuli (3, 4) , however, the tissue was not necessarily selected for the presence of an airway. Hence, we adapted an integrated model system that allows for the assumption that all structural components of the lung, including ASM and epithelial cells as well as parenchymal tissue, are present and intact. Thus an advantage to this study, in addition to the homogeneity between samples, is the presence of a small airway (Ϸ Յ1-mm diameter) with which we could also measure contractile and relaxing responses. Although we recognize that TLR3 and non-TLR3 pathways are activated by poly(I:C), a limitation of the PCLS model is the inability to definitely show TLR3 specificity on any one cell type. Thus, using single cell preparations of human ASM cells, specificity was demonstrated by levels of MIP-1␣ production returning to those of TNF␣ alone by the inhibition of poly(I:C) ϩ TNF␣-induced MIP-1␣ production in the presence of a monoclonal TLR3 receptor antibody. antagonists, either biological or small molecule reagents, and as such, the variance observed is likely due to low-and high-affinity Fc receptor expression on human ASM. This is clearly demonstrated in the controls that were treated with an isotype-matched antibody revealing considerable variance. Apart from specifically knocking down TLR3 expression using small interfering RNA (siRNA), we have little option in showing selectivity of poly(I:C) for TLR3 activation. Specificity of poly(I:C) to TLR3 in our integrated lung slice system is therefore assumed to be consistent with observations using cultured ASM or epithelial cells. In addition, dsRNA exposure of peripheral blood mononuclear cells induces a characteristic profile (e.g., expression of IL-12, IFN-␥, etc.), reflecting the possible contribution of a variety of immune cells (9) .
The contribution of TLR3 activation to the integrated respiratory immune response remains unknown, but it may alter the balance of Th1-to-Th2 responses in favor of the Th1-dominated phenotype. For example, TLR3
Ϫ/Ϫ mice infected with respiratory syncytial virus (RSV) infection had increased eosinophils IL-5 and IL-13 and mucus production compared with wild-type controls (22) . This is consistent with others who showed that systemic pretreatment with a TLR3 agonist protects mice against subsequent OVA sensitization, with reduced eosinophils, IL-5, and goblet cell numbers (24) .
Effect of poly(I:C) on human small airway sensitivity. It was hypothesized that the increase of inflammatory cytokines and chemokines would affect ASM contractility and/or relaxation in human small airways. However, poly(I:C) had little effect on E max or log EC 50 values for carbachol-and isoproterenolevoked contraction and relaxation responses, respectively. This is the first report, to our knowledge, to address the effects of a TLR3 agonist on human small airway function ex vivo. Previously, studies reported that poly(I:C) (25 g/ml; 24 h) increases muscarinic M 3 and decreases muscarinic M 2 receptor expression in cultured ASM cells (16) . The muscarinic receptor expression was time-dependent with a maximum response after 24 h of stimulation. Despite performing our studies at 24 h, poly(I:C) had little effect on excitation-contraction coupling ex vivo at two concentrations. In vitro cultured ASM cells and ASM cells ex vivo likely have important physiological differences such as differences in cell-cell interactions that may account for differential responses to TLR3 stimulation. For example, poly(I:C) increased airway sensitivity to the contractile agonist bradykinin in murine isolated tracheal rings but only after a 4-day incubation (2). Our results are consistent, however, with those of others who have examined the in vivo responses of rats to intratracheal aerosols of poly(I:C) and observed that TLR3 agonist does not modulate the muscarinic contractile response (25) . Unlike the study by Morishima and colleagues (16) , the rat in vivo study (25) , like this current study, examined the effects of dsRNA in a whole tissue system. Although muscarinic receptors may be altered in ASM cells, opposing responses from other cell types present in lung slices or in the whole animal may be responsible for inhibition of alterations in ASM cell function. It is likely that, for example, afferent vagal fibers that also express M 2 receptor in the airways (7) , and for which function is impaired by viruses (7, 11) , would be lost during explant incubation.
In human ASM treated with poly(I:C), acetylcholine inhibition of forskolin-stimulated cyclic AMP accumulation was reduced (16) . These data suggest that the adenylyl cyclase signaling pathway was potentially enhanced, but an effect of poly(I:C) on ␤-adrenergic receptor-activated relaxation has not been reported. Using ex vivo human PCLS in our studies, we found poly(I:C) agonist had little effect on airway relaxation. Thus even at high concentrations that may activate TLR3 and non-TLR3 pathways, there was no direct effect on agonistmediated airway tone.
We have demonstrated that poly(I:C) has little effect on ASM contraction or relaxation despite induction of inflammatory mediators. The augmentation of these mediators in the presence of contractile ASM cells would suggest otherwise, as previous work has demonstrated an increase in ASM contraction in the presence of TNF␣ (1, 5, 10) . Although large amounts of TNF␣ were released from the human lung slices during poly(I:C) incubation, the concentrations required to produce AHR may not have been achieved. Indeed, Chen and colleagues (5) demonstrated no increase in murine tracheal contraction at concentrations of 10 g/ml but did show enhancement at a half a log increase in the concentration, as did our parallel study of in vitro TNF␣ incubation with the lung slices, which we believe to be the first time reported in human small airways. IL-13 preincubation also demonstrated that AHR is achievable in our human lung slice model. This result, which has also been shown in ASM (15, 28) , is thought to be demonstrated herein for the first time in human small airways. It is worth noting that our findings failed to show a poly(I:C)-induced increase in IL-13, so its absence, in part, could be responsible for the lack of airway hypersensitivity. It is also worth noting the increased levels of IL-10 in the present study. IL-10 inhibits the synthesis of proinflammatory cytokines such as TNF␣ (21, 32) . Unlike cultured cells, the whole tissue may contain mast cells, and hence the effective cytokine release may be lessened by the presence of IL-10, which would not be seen in single cell preparations. Intriguingly, despite an increase in neutrophils in rat bronchoalveolar lavage fluid, which has been shown to correlate with increased airway sensitivity (30) , following poly(I:C) instillation, agonist-induced airway function in vivo was not altered compared with diluent-treated samples (25) , suggesting that TLR3-activated responses in multicellular systems may be different than single cellular preparations. In other studies, the effect of poly(I:C) in human cell lines showed a modest 5-fold increase in RANTES/CCL5 in ASM (18) ; however, our study showed a 50-fold increase demonstrating the importance of the integrated and complicated model used in the present study. Niimi and colleagues (18) also demonstrated increased levels of eotaxin/CCL11 in BEAS-2B and smooth muscle cell lines, however, the present study failed to note any detectable levels. These examples, therefore, demonstrate a differential regulation of inflammatory mediator expression and muscarinic-dependent ASM contractile responses.
The mechanism by which poly(I:C) would elicit an increase in airway sensitivity is thought to be by the production of mediators released from the tissue following its incubation. To determine whether airways contained in PCLS were able to be affected by local mediator releases, we used a model of passive sensitization as previously described (31) . Crosslinking of IgE with anti-IgE is thought to degranulate mast cells present in the tissue and cause the release of histamine. This local release of histamine causes the airway to contract.
In this study, as a control for the model, we have shown that a local release of a mediator can cause an effect on the tissue.
Despite the benefits of the PCLS model, we do recognize that other limitations exist. PCLS has the advantage of being a complex multicell system; however, it offers little opportunity to determine the relative cell contributions to the outcome. Cell-specific neutralizing antibodies are also not feasible in this model, and although all cell types are found in the lung slice, trafficking leukocytes are absent. Unlike single cell preparations, diffusion gradients are increased in PCLS warranting an increase in stimuli concentrations to yield the same response.
In summary, using an ex vivo human lung slice model, we show that poly(I:C) induces inflammatory cytokine and chemokine expression, but this is uncoupled from ASM contraction or relaxation responses in airways of 1 mm or less. Although no direct correlation could be obtained among cytokine profiles and airway sensitivity in our study, the model provides a platform for screening that may be important in characterizing therapeutic targets for COPD and asthma.
